FDA Expands Dupilumab for EoE to Younger Children FDA Expands Dupilumab for EoE to Younger Children

Dupilumab is now indicated for the treatment of eosinophilic esophagitis in children as young as 1 year and weighing at least 15 kg.Medscape Medical News
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Gastroenterology Source Type: news